Peer-reviewed Artikel
Stem Cells 2007; 25(11):2910-2918.
Selective targeting of adenoviral vectors to neural precursor cells in the hippocampus of adult mice: New prospects for in situ gene therapy.
Schmidt A, Haas SJ-P, Hildebrandt S, Scheibe J, Eckhoff B, Kempermann G, Wree A, Pützer BM.Discov Med. 2006; 6(33):123-127.
Targeting E2F1 death signaling: Opposing role in cancer control and neurodegeneration.
Pützer BM.Clin Pract Oncol. 2006; 3:564-574.
Cancer targeting: impact of oncogenic RET for medullary thyroid carcinoma therapy.
Drosten M, Pützer BM.Proteomics. 2006; 6:5735-5745.
Proteomic analysis of the E2F1 response in p53-negative cancer cells: new aspects in the regulation of cell survival and death.
Li Z, Kreutzer M, Mikkat S, Miše N, Glocker, MO, Pützer, BM.Oncogene. 2006; 25:6637-6647.
Evaluation of potential mechanisms underlying genotype-phenotype correlations in multiple endocrine neoplasia type 2.
Miše N, Drosten M, Racek T, Tannapfel A, Pützer BM.Trends Mol Med. 2006; 12:177-185.
E2F1-related apoptosis: turning killers into therapeutics.
Stanelle J, Pützer BM.Apoptosis. 2006; 11:235-244.
Adenovirus-mediated TA-p73beta gene transfer increases chemosensitivity of human malignant melanomas.
Tuve S, Racek T, Niemetz A, Schultz J, Soengas MS, Pützer BMJ Biol Chem. 2005; 280:40402-40405.
C-terminal p73 isoforms repress transcriptional activity of the human telomerase reverse transcriptase (hTERT) promoter.
Racek T, Miše N, Li Z, Stoll A, Putzer BMHum Gene Ther. 2005; 16:1267-1275.